



Contents

UNIVERSIDAD MAYOR DE SAN SIMÓN					
FACULTAD DE MEDICINA					
INVENTARIO: Biblioteca "Julio Rodríguez Rivas"					
07	13	01	101	597679	
Código de Inventario					
5	11	09	Bs.	15.-	
Día Mes Año			Valor		

1. Introduction	1
2. Background	3
3. Definition of osteoporosis and related terms	5
3.1 Conceptual definition of osteoporosis	5
3.2 Operational definition of osteoporosis	5
3.3 Intervention thresholds	6
3.4 Intervention categories	6
4. Preclinical studies	7
4.1 Introduction and aims	7
4.2 Studies <i>in vitro</i>	8
4.2.1 Studies on bone resorption	8
4.2.2 Studies on bone formation	9
4.3 Animal models	9
4.3.1 Animal species	9
4.3.2 Experimental techniques	10
4.3.3 End-points	10
4.3.4 Statistics	11
4.3.5 Ethical considerations	11
4.4 Specific recommendations for animal models	11
4.4.1 The adult oophorectomized rat	11
4.4.2 Other rat models	12
4.4.3 Mouse models	12
4.4.4 Non-rodent models	12
4.5 Study design	13
4.5.1 Intervention schedule	13
4.5.2 Dosage	13
4.5.3 Duration of treatment	14

4.6	End-points	14
4.6.1	Assessment of bone mass and bone mineral	14
4.6.2	Bone histology and microarchitecture	14
4.6.3	Biomechanical testing of bone strength	15
4.6.4	Biochemical indices of skeletal metabolism	17
4.6.5	Fracture healing	18
4.7	Pharmacokinetics	18
4.8	Studies of long-term bone safety	19
4.9	Other toxicological studies	19
4.10	Minimal preclinical requirements for clinical evaluation in phase III	20
5.	Clinical trials in osteoporosis	21
5.1	Introduction	21
5.2	Bone mass and fracture	22
5.3	Techniques used in the assessment of osteoporosis and response to interventions	23
5.3.1	Single-energy absorptiometry	24
5.3.2	Dual-energy absorptiometry	24
5.3.3	Other techniques	25
5.3.4	Limitations of techniques	25
5.3.5	Sites of bone mineral measurements	26
5.4	Fracture assessment	27
5.4.1	Fractures as entry criteria and end-points	27
5.4.2	Vertebral fractures	27
5.5	Height	29
5.6	Quality of life	29
5.7	Other measurements	30
5.7.1	Bone biopsy	30
5.7.2	Biochemical indices of bone turnover	31
5.8	General principles of trial design	31
5.8.1	Population to be studied	32
5.8.2	Treatment regimen	33
5.8.3	Study design	33
5.8.4	Duration of studies	34
5.8.5	Sample size	34
5.8.6	Frequency of measurement	35
5.8.7	Safety	36
5.9	Non-pharmacological interventions	36
5.10	Good clinical practice	36

6. Phase I and phase II studies	38
6.1 Phase I studies	38
6.2 Phase II studies	38
6.3 Basic conditions	39
7. Phase III studies in severe (established) osteoporosis	41
7.1 Introduction	41
7.2 Population studied	41
7.3 Basic conditions	41
7.4 End-points	42
7.4.1 Reduction in the rate of fracture	42
7.4.2 Increase in bone mass	43
7.4.3 Prevention of bone loss or reduction in the rate of bone loss	43
7.5 Study design	44
7.5.1 Duration	44
7.5.2 Site of measurement	44
7.6 Other types of studies in severe (established) osteoporosis	44
7.6.1 Reduction of extraskeletal risks in osteoporosis	44
7.6.2 Symptomatic end-points	44
7.7 Safety and clinical pharmacology	44
8. Phase III studies in osteoporosis without fragility fractures	46
8.1 Introduction	46
8.2 Population studied	46
8.3 Basic conditions	46
8.4 End-points	47
8.5 Study design	47
8.6 Safety and clinical pharmacology	47
9. Phase III studies in low bone mass (osteopenia)	49
9.1 Introduction	49
9.2 Population studied	49
9.3 Basic conditions	50
9.4 End-points	50
9.5 Study design	50
9.6 Duration of studies, including interruption of treatment	51
9.7 Safety	51
10. Phase III clinical trials in subjects with normal bone mass	52
10.1 Introduction	52
10.2 Population studied	52

10.3 Basic conditions	53
10.4 End-points	53
10.5 Study design	53
10.6 Duration of studies, including interruption of treatment	53
10.7 Safety	54
11. Phase IV studies	55
11.1 Introduction	55
11.2 Aims	55
11.2.1 Efficacy with continued treatment	55
11.2.2 Efficacy after discontinuation of treatment	55
11.2.3 Need for retreatment	56
11.2.4 Safety and other end-points	56
11.3 Type of study	56
11.3.1 Uncontrolled trials	56
11.3.2 Cohort study	57
11.3.3 Case-control study	57
11.3.4 Randomized trials	57
11.4 Sample size and statistical considerations	57
12. Glossary of terms	58
References	65
Acknowledgements	67
Annex. Recommendation for future guideline development	68